...
首页> 外文期刊>Cell death & disease. >Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo
【24h】

Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo

机译:多靶标化合物的协同作用在人体内和体外都产生了有效的人NSCLC化合物组合

获取原文
           

摘要

By screening a collection of one hundred combinations of thiazolidinone compounds, we identified one combination (M4) that synergistically inhibited the growth of H460 and H460/TaxR cells and tumor growth in H460/TaxR xenograft mice. A whole genome microarray assay showed that genes involved in negative regulation of microtubule polymerization or depolymerization, intracellular protein kinase cascade, positive regulation of histone acetylation, cell cycle arrest and apoptosis were upregulated. Further analysis proved that the four compounds act as either microtubule polymerization inhibitors or histone deacetylase inhibitors. They act synergistically targeting multiple proteins and leading to the regulation of cell cycle checkpoint proteins, including p53, p21, cdc25C and cdc2, the activation of caspases, JNK, p38 cascades and the inactivation of Akt. These events resulted in the G2/M cell cycle arrest and cell apoptosis. These data provide a new strategy for discovering anticancer drugs and drug combinations for drug-resistant cancers.
机译:通过筛选一百种噻唑烷酮化合物组合的集合,我们确定了一种协同抑制H460 / TaxR异种移植小鼠中H460和H460 / TaxR细胞的生长以及肿瘤生长的组合(M4)。全基因组微阵列分析表明,参与微管聚合或解聚负调控,细胞内蛋白激酶级联,组蛋白乙酰化正调控,细胞周期停滞和凋亡的基因上调。进一步的分析证明,这四种化合物可作为微管聚合抑制剂或组蛋白脱乙酰基酶抑制剂。它们协同作用靶向多种蛋白质,并导致细胞周期检查点蛋白质(包括p53,p21,cdc25C和cdc2)的调节,胱天蛋白酶,JNK,p38级联的激活和Akt的失活。这些事件导致G2 / M细胞周期停滞和细胞凋亡。这些数据为发现抗癌药物的抗癌药物和药物组合提供了新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号